#Gilead Sciences

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.

The single-tablet regimen includes the experimental bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

However, Gilead Sciences, the brand-name manufacturer of Truvada, insists a generic version “will not be immediately available.”

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

Pharmaceutical giant Gilead Sciences has awarded over $22 million in grants for 12 HIV-cure-focused research projects.

About 90,000 people in the United States are taking Truvada to prevent getting HIV.

Funding will support these 12 research- and community-based projects.

Who are the top 10 global funders, and where do those millions go? The FCAA’s latest findings will surprise you.

HIV-positive people 50 and older who switched from Truvada to Descovy in a recent trial reaped health benefits.

Even those who did not qualify for a treatment shorter than 12 weeks did well on the regimen in a real-world study.

Danish biotech company Genmab’s so-called bispecific antibody could expand Gilead’s HIV treatment portfolio

$40M focuses on keeping girls in school in sub-Saharan Africa.